|
시장보고서
상품코드
1861257
세계의 신경유전학적 검사 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Neurogenetic Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 신경유전학적 검사 시장 규모는 2024년에 6억 8,500만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 11.7%로 성장하여 2031년까지 15억 100만 달러로 확대될 것으로 예측됩니다.
신경유전학적 검사란 신경질환과 관련된 유전자를 분석, 해석하기 위한 분자-유전체 진단법입니다. 이 검사를 통해 개인이 신경퇴행성 질환, 간질, 지적장애, 자폐스펙트럼장애, 운동장애, 특정 유전성 신경장애를 유발할 수 있는 유전자 돌연변이를 보유하고 있는지 여부를 확인할 수 있습니다. 신경유전학적 검사의 가치는 질병의 조기 검진 및 임상 진단뿐만 아니라 의사가 개인별 맞춤 치료 계획을 수립하는 데 도움을 주고, 가족이 유전적 위험 평가 및 생식 계획을 세우는 데 도움을 줄 수 있다는 점에서도 가치가 있습니다.
세계 주요 신경유전학 검사 업체로는 Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp 등이 있습니다. 세계 상위 5개 업체의 점유율은 약 30%를 차지하고 있습니다.
가장 큰 시장은 북미로, 점유율이 30%를 넘습니다. 그 뒤를 이어 유럽과 아시아태평양이 각각 약 32%, 20%의 시장 점유율을 차지하고 있습니다.
제품별로는 엑솜 시퀀싱이 가장 큰 부문으로 약 45%의 점유율을 차지하고 있습니다. 용도별로는 병원이 가장 큰 사용처로 45% 이상의 점유율을 차지하고 있으며, 전문 클리닉, 연구기관, 진단 검사실이 그 뒤를 잇고 있습니다.
알츠하이머병, 파킨슨병, 간질, 자폐스펙트럼장애 등 질환의 임상적 부담이 증가하는 가운데, 유전자 검사는 조기 진단, 위험 예측, 맞춤 치료를 위한 중요한 도구가 되고 있습니다. 차세대 시퀀싱(NGS), 전 엑솜 시퀀싱(WES), 전장유전체 시퀀싱(WGS)의 발전으로 비용이 크게 절감되는 동시에 정확도와 효율성이 향상되어 임상 현장에서의 채택이 가속화되고 있습니다. 동시에 제약회사와 의료 서비스 제공자들은 잠재적인 치료 표적과 동반진단을 식별하기 위해 의약품 개발 및 임상시험에 신경유전학적 검사를 통합하려는 움직임이 강화되고 있습니다.
이 보고서는 신경유전학 검사 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총매출액, 주요 기업의 기업 점유율과 순위에 초점을 맞추고, 지역별, 국가별, 종류별, 용도별 신경유전학적 검사 분석을 포함합니다.
신경유전학 검사 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 신경유전학 검사 관련 사업/성장 전략 수립, 시장 경쟁 평가, 현재 시장 내 자사 위치 분석, 그리고 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Quest Diagnostics
- Mayo Clinic
- GeneDx
- Illumina
- Labcorp(Invitae/MNG Laboratories)
- MedGenome Labs
- Connecticut Children's
- CENTOGENE
- Victorian Clinical Genetics Services
- PacBio
유형별 부문
- 엑솜 시퀀싱
- 전장 유전체 시퀀싱
- RNA 시퀀싱
- 일반적인 DNA 검사
용도별 부문
- 병원
- 전문 클리닉
- 연구기관
- 진단 실험실
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Neurogenetic Testing was estimated to be worth US$ 685 million in 2024 and is forecast to a readjusted size of US$ 1501 million by 2031 with a CAGR of 11.7% during the forecast period 2025-2031.
Neurogenetic testing is a molecular and genomic diagnostic approach used to analyze and interpret genes associated with neurological disorders. This testing helps identify whether an individual carries genetic mutations that may cause neurodegenerative diseases, epilepsy, intellectual disability, autism spectrum disorders, movement disorders, and certain hereditary neuropathies. The value of neurogenetic testing lies not only in early disease screening and clinical diagnosis, but also in guiding physicians to develop personalized treatment plans and assisting families with genetic risk assessment and reproductive planning.
Global neurogenetic testing players include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina and Labcorp, etc. Global top five manufacturers hold a share about 30%.
The largest market is North America, has a share over 30%, followed by Europe and Asia Pacific, with around 32% and 20% market share respectively.
In terms of product, Exome Sequencing is the largest segment, with a share about 45%. And in terms of application, the largest application is Hospitals, has a share over 45%, followed by Specialty Clinics, Research Institutes and Diagnostics Laboratories.
With the growing clinical burden of diseases such as Alzheimer's, Parkinson's, epilepsy, and autism spectrum disorders, genetic testing is becoming a critical tool for early diagnosis, risk prediction, and personalized treatment. Advances in next-generation sequencing (NGS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) have significantly reduced costs while improving accuracy and efficiency, accelerating adoption in clinical practice. At the same time, pharmaceutical companies and healthcare providers are increasingly integrating neurogenetic testing into drug development and clinical trials to identify potential therapeutic targets and companion diagnostics.
This report aims to provide a comprehensive presentation of the global market for Neurogenetic Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neurogenetic Testing by region & country, by Type, and by Application.
The Neurogenetic Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurogenetic Testing.
Market Segmentation
By Company
- Quest Diagnostics
- Mayo Clinic
- GeneDx
- Illumina
- Labcorp (Invitae/MNG Laboratories)
- MedGenome Labs
- Connecticut Children's
- CENTOGENE
- Victorian Clinical Genetics Services
- PacBio
Segment by Type
- Exome Sequencing
- Whole Genome Sequencing
- RNA Sequencing
- General DNA Testing
Segment by Application
- Hospitals
- Specialty Clinics
- Research Institutes
- Diagnostics Laboratories
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neurogenetic Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Neurogenetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Neurogenetic Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Neurogenetic Testing Product Introduction
- 1.2 Global Neurogenetic Testing Market Size Forecast (2020-2031)
- 1.3 Neurogenetic Testing Market Trends & Drivers
- 1.3.1 Neurogenetic Testing Industry Trends
- 1.3.2 Neurogenetic Testing Market Drivers & Opportunity
- 1.3.3 Neurogenetic Testing Market Challenges
- 1.3.4 Neurogenetic Testing Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Neurogenetic Testing Players Revenue Ranking (2024)
- 2.2 Global Neurogenetic Testing Revenue by Company (2020-2025)
- 2.3 Key Companies Neurogenetic Testing Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Neurogenetic Testing Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Neurogenetic Testing
- 2.6 Neurogenetic Testing Market Competitive Analysis
- 2.6.1 Neurogenetic Testing Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Neurogenetic Testing Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurogenetic Testing as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Exome Sequencing
- 3.1.2 Whole Genome Sequencing
- 3.1.3 RNA Sequencing
- 3.1.4 General DNA Testing
- 3.2 Global Neurogenetic Testing Sales Value by Type
- 3.2.1 Global Neurogenetic Testing Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Neurogenetic Testing Sales Value, by Type (2020-2031)
- 3.2.3 Global Neurogenetic Testing Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospitals
- 4.1.2 Specialty Clinics
- 4.1.3 Research Institutes
- 4.1.4 Diagnostics Laboratories
- 4.2 Global Neurogenetic Testing Sales Value by Application
- 4.2.1 Global Neurogenetic Testing Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Neurogenetic Testing Sales Value, by Application (2020-2031)
- 4.2.3 Global Neurogenetic Testing Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Neurogenetic Testing Sales Value by Region
- 5.1.1 Global Neurogenetic Testing Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Neurogenetic Testing Sales Value by Region (2020-2025)
- 5.1.3 Global Neurogenetic Testing Sales Value by Region (2026-2031)
- 5.1.4 Global Neurogenetic Testing Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Neurogenetic Testing Sales Value, 2020-2031
- 5.2.2 North America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Neurogenetic Testing Sales Value, 2020-2031
- 5.3.2 Europe Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Neurogenetic Testing Sales Value, 2020-2031
- 5.4.2 Asia Pacific Neurogenetic Testing Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Neurogenetic Testing Sales Value, 2020-2031
- 5.5.2 South America Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Neurogenetic Testing Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Neurogenetic Testing Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Neurogenetic Testing Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Neurogenetic Testing Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Neurogenetic Testing Sales Value, 2020-2031
- 6.3.2 United States Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Neurogenetic Testing Sales Value, 2020-2031
- 6.4.2 Europe Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Neurogenetic Testing Sales Value, 2020-2031
- 6.5.2 China Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Neurogenetic Testing Sales Value, 2020-2031
- 6.6.2 Japan Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Neurogenetic Testing Sales Value, 2020-2031
- 6.7.2 South Korea Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Neurogenetic Testing Sales Value, 2020-2031
- 6.8.2 Southeast Asia Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Neurogenetic Testing Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Neurogenetic Testing Sales Value, 2020-2031
- 6.9.2 India Neurogenetic Testing Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Neurogenetic Testing Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Quest Diagnostics
- 7.1.1 Quest Diagnostics Profile
- 7.1.2 Quest Diagnostics Main Business
- 7.1.3 Quest Diagnostics Neurogenetic Testing Products, Services and Solutions
- 7.1.4 Quest Diagnostics Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.1.5 Quest Diagnostics Recent Developments
- 7.2 Mayo Clinic
- 7.2.1 Mayo Clinic Profile
- 7.2.2 Mayo Clinic Main Business
- 7.2.3 Mayo Clinic Neurogenetic Testing Products, Services and Solutions
- 7.2.4 Mayo Clinic Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.2.5 Mayo Clinic Recent Developments
- 7.3 GeneDx
- 7.3.1 GeneDx Profile
- 7.3.2 GeneDx Main Business
- 7.3.3 GeneDx Neurogenetic Testing Products, Services and Solutions
- 7.3.4 GeneDx Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.3.5 GeneDx Recent Developments
- 7.4 Illumina
- 7.4.1 Illumina Profile
- 7.4.2 Illumina Main Business
- 7.4.3 Illumina Neurogenetic Testing Products, Services and Solutions
- 7.4.4 Illumina Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.4.5 Illumina Recent Developments
- 7.5 Labcorp (Invitae/MNG Laboratories)
- 7.5.1 Labcorp (Invitae/MNG Laboratories) Profile
- 7.5.2 Labcorp (Invitae/MNG Laboratories) Main Business
- 7.5.3 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Products, Services and Solutions
- 7.5.4 Labcorp (Invitae/MNG Laboratories) Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.5.5 Labcorp (Invitae/MNG Laboratories) Recent Developments
- 7.6 MedGenome Labs
- 7.6.1 MedGenome Labs Profile
- 7.6.2 MedGenome Labs Main Business
- 7.6.3 MedGenome Labs Neurogenetic Testing Products, Services and Solutions
- 7.6.4 MedGenome Labs Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.6.5 MedGenome Labs Recent Developments
- 7.7 Connecticut Children's
- 7.7.1 Connecticut Children's Profile
- 7.7.2 Connecticut Children's Main Business
- 7.7.3 Connecticut Children's Neurogenetic Testing Products, Services and Solutions
- 7.7.4 Connecticut Children's Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.7.5 Connecticut Children's Recent Developments
- 7.8 CENTOGENE
- 7.8.1 CENTOGENE Profile
- 7.8.2 CENTOGENE Main Business
- 7.8.3 CENTOGENE Neurogenetic Testing Products, Services and Solutions
- 7.8.4 CENTOGENE Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.8.5 CENTOGENE Recent Developments
- 7.9 Victorian Clinical Genetics Services
- 7.9.1 Victorian Clinical Genetics Services Profile
- 7.9.2 Victorian Clinical Genetics Services Main Business
- 7.9.3 Victorian Clinical Genetics Services Neurogenetic Testing Products, Services and Solutions
- 7.9.4 Victorian Clinical Genetics Services Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.9.5 Victorian Clinical Genetics Services Recent Developments
- 7.10 PacBio
- 7.10.1 PacBio Profile
- 7.10.2 PacBio Main Business
- 7.10.3 PacBio Neurogenetic Testing Products, Services and Solutions
- 7.10.4 PacBio Neurogenetic Testing Revenue (US$ Million) & (2020-2025)
- 7.10.5 PacBio Recent Developments
8 Industry Chain Analysis
- 8.1 Neurogenetic Testing Industrial Chain
- 8.2 Neurogenetic Testing Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Neurogenetic Testing Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Neurogenetic Testing Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
